A citation-based method for searching scientific literature

Haris Hatic, Devi Sampat, Gaurav Goyal. Ann Transl Med 2021
Times Cited: 9







List of co-cited articles
40 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn,[...]. N Engl J Med 2020
611
33

The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Justin Kline, James Godfrey, Stephen M Ansell. Blood 2020
75
33

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan, Xiaofang Wang, Yafei Wang, Qi Deng. Front Immunol 2021
11
22

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
765
22

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
246
22

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Yaqing Cao, Wenyi Lu, Rui Sun, Xin Jin, Lin Cheng, Xiaoyuan He, Luqiao Wang, Ting Yuan, Cuicui Lyu, Mingfeng Zhao. Front Oncol 2019
67
22

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.
Elad Jacoby, Sang M Nguyen, Thomas J Fountaine, Kathryn Welp, Berkley Gryder, Haiying Qin, Yinmeng Yang, Christopher D Chien, Alix E Seif, Haiyan Lei,[...]. Nat Commun 2016
252
22


Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
Zhenling Guo, Sanfang Tu, Siyao Yu, Liufang Wu, Wanying Pan, Ning Chang, Xuan Zhou, Chaoyang Song, Yuhua Li, Yanjie He. Cancer Sci 2021
7
28

4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Gongbo Li, Justin C Boucher, Hiroshi Kotani, Kyungho Park, Yongliang Zhang, Bishwas Shrestha, Xuefeng Wang, Lawrence Guan, Nolan Beatty, Daniel Abate-Daga,[...]. JCI Insight 2018
63
22

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.
Joel Crespo, Haoyu Sun, Theodore H Welling, Zhigang Tian, Weiping Zou. Curr Opin Immunol 2013
423
22

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.
Mohamad Hamieh, Anton Dobrin, Annalisa Cabriolu, Sjoukje J C van der Stegen, Theodoros Giavridis, Jorge Mansilla-Soto, Justin Eyquem, Zeguo Zhao, Benjamin M Whitlock, Matthew M Miele,[...]. Nature 2019
243
22

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Guoxing Zhao, Runhong Wei, Lei Feng, Yi Wu, Feng He, Mingxing Xiao, Zhi Cheng. Cancer Immunol Immunother 2022
7
28

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
475
22

CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Guoqing Wei, Yanlei Zhang, Houli Zhao, Yiyun Wang, Yandan Liu, Bin Liang, Xiujian Wang, Huijun Xu, Jiazhen Cui, Wenjun Wu,[...]. Cancer Immunol Res 2021
16
22

CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report.
Jia Wang, Qi Deng, Yan-Yu Jiang, Rui Zhang, Hai-Bo Zhu, Juan-Xia Meng, Yu-Ming Li. Oncol Lett 2019
21
22

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
Haibo Zhu, Haobin Deng, Juan Mu, Cuicui Lyu, Yanyu Jiang, Qi Deng. Onco Targets Ther 2021
5
40

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Carl DeSelm, M Lia Palomba, Joachim Yahalom, Mohamad Hamieh, Justin Eyquem, Vinagolu K Rajasekhar, Michel Sadelain. Mol Ther 2018
104
22

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang,[...]. J Hematol Oncol 2020
117
22

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Elena J Orlando, Xia Han, Catherine Tribouley, Patricia A Wood, Rebecca J Leary, Markus Riester, John E Levine, Muna Qayed, Stephan A Grupp, Michael Boyer,[...]. Nat Med 2018
272
22

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
22

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
Marco Ruella, Jun Xu, David M Barrett, Joseph A Fraietta, Tyler J Reich, David E Ambrose, Michael Klichinsky, Olga Shestova, Prachi R Patel, Irina Kulikovskaya,[...]. Nat Med 2018
297
22

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Caron A Jacobson, Julio C Chavez, Alison R Sehgal, Basem M William, Javier Munoz, Gilles Salles, Pashna N Munshi, Carla Casulo, David G Maloney, Sven de Vos,[...]. Lancet Oncol 2022
55
22

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
980
22

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
621
22

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson, Constance M Yuan, Sneha Ramakrishna, Pamela Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates,[...]. Nat Med 2018
743
22


CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
Cameron J Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M Budiarto,[...]. J Clin Invest 2016
22

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
22

Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.
Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä. Clin Cancer Res 2022
6
33

Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.
Robert Weinkove, Philip George, Nathaniel Dasyam, Alexander D McLellan. Clin Transl Immunology 2019
142
22

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Jing Pan, Qing Niu, Biping Deng, Shuangyou Liu, Tong Wu, Zhiyong Gao, Zhaoli Liu, Yue Zhang, Xiaomin Qu, Yanlei Zhang,[...]. Leukemia 2019
113
22

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.
Alan G Ramsay, Andrew J Clear, Gavin Kelly, Rewas Fatah, Janet Matthews, Finlay Macdougall, T Andrew Lister, Abigail M Lee, Maria Calaminici, John G Gribben. Blood 2009
189
22

Immunomodulatory Drugs for the Treatment of B Cell Malignancies.
Nikolaos Ioannou, Khushi Jain, Alan G Ramsay. Int J Mol Sci 2021
9
22

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Alan G Ramsay, Amy J Johnson, Abigail M Lee, Güllü Gorgün, Rifca Le Dieu, William Blum, John C Byrd, John G Gribben. J Clin Invest 2008
456
22

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.
Cédric Ménard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia Papa, Maelle Latour, Nadège Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest,[...]. Blood Adv 2021
7
28

Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.
Yingyue Liu, Xiangxiang Zhou, Xin Wang. J Hematol Oncol 2021
17
22

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, JiBiao Wu, Zhen Zhang. Front Pharmacol 2021
35
22

Mechanisms of resistance to CAR T cell therapy.
Nirali N Shah, Terry J Fry. Nat Rev Clin Oncol 2019
389
22

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicole S Nicholas, Benedetta Apollonio, Alan G Ramsay. Biochim Biophys Acta 2016
76
22

Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Ahmed Gamal Elsayed, Roma Srivastava, Muhammad Omer Jamil. Curr Oncol Rep 2017
6
16

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.
Ana Brusic, Ursula Hainz, Martha Wadleigh, Donna Neuberg, Mei Su, Christine M Canning, Daniel J Deangelo, Richard M Stone, Jeng-Shin Lee, Richard C Mulligan,[...]. Oncoimmunology 2012
14
11

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.
Jean-Claude Chomel, Marie-Laure Bonnet, Nathalie Sorel, Angelina Bertrand, Marie-Claude Meunier, Serge Fichelson, Michael Melkus, Annelise Bennaceur-Griscelli, François Guilhot, Ali G Turhan. Blood 2011
149
11


Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study.
Elena Marinelli Busilacchi, Andrea Costantini, Nadia Viola, Benedetta Costantini, Jacopo Olivieri, Luca Butini, Giorgia Mancini, Ilaria Scortechini, Martina Chiarucci, Monica Poiani,[...]. Biol Blood Marrow Transplant 2018
20
11

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, Katherine Hastings, Katerina Politi, David L Rimm, Lieping Chen, Ignacio Melero, Kurt A Schalper, Roy S Herbst. Clin Cancer Res 2019
305
11

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
C I-U Chen, S Koschmieder, L Kerstiens, M Schemionek, B Altvater, S Pscherer, J Gerss, H T Maecker, W E Berdel, H Juergens,[...]. Leukemia 2012
47
11


Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet,[...]. Lancet Oncol 2010
11

Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.
Paulina Kwaśnik, Krzysztof Giannopoulos. J Pers Med 2021
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.